Wenhu Zhan

List of Publications by Year in Descending Order

19 papers	250 citations	9 h-index	15 g-index
20 ext. papers	338 ext. citations	7.7 avg, IF	2.38 L-index

#	Paper	IF	Citations
19	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. *Angewandte Chemie - International Edition*, **2021**, 60, 9279-9283	16.4	5
18	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. *Angewandte Chemie*, **2021**, 133, 9365-9369	3.6	0
17	Macrocyclic Peptides that Selectively Inhibit the Proteasome. *Journal of Medicinal Chemistry*, **2021**, 64, 6262-6272	8.3	3
16	Discovery of -((3,4)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. *Journal of Medicinal Chemistry*, **2021**, 64, 12163-12180	8.3	3
15	Structure-Activity Relationships of Noncovalent Immunoproteasome i-Selective Dipeptides. *Journal of Medicinal Chemistry*, **2020**, 63, 13103-13123	8.3	7
14	Selective Phenylimidazole-Based Inhibitors of the Proteasome. *Journal of Medicinal Chemistry*, **2019** , 62, 9246-9253	8.3	8
13	Improvement of Asparagine Ethylenediamines as Anti-malarial -Selective Proteasome Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 6137-6145	8.3	19
12	Phenotypic Screening-Based Identification of 3,4-Disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis. *Journal of Medicinal Chemistry*, **2019**, 62, 3268-3285	8.3	5
11	Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. *Journal of Medicinal Chemistry*, **2019**, 62, 7264-7288	8.3	13
10	Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 180, 72-85	6.8	10
9	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6863-E6870	11.5	37
8	Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. *Nature Communications*, **2017**, 8, 1692	17.4	36
7	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 117, 47-58	6.8	19
6	Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors. *Chemical Biology and Drug Design*, **2015**, 85, 770-9	2.9	8
5	Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: toward the discovery of novel Akt1 inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 75, 11-20	6.8	37
4	Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 73, 167-76	6.8	14
3	Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 4323-9	3.4	18

2	Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5279-82	2.9	7
1	Artemisinin-based hybrids produce intracellular proteasome inhibitors that overcome resistance in Plasmodium falciparum		1